ClinicalTrials.gg
RecruitingNCT06338631OB-KIDUpdated Aug 3, 2025

Early Detection of Renal Abnormalities in Metabolically Healthy and Unhealthy Weight Excess"

An observational study in Obesity, sponsored by Istituto Auxologico Italiano. Recruiting at 2 sites in Italy. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Obesity by Istituto Auxologico Italiano — 11 open to participants now, 12 under way, none of them phase 3. Obesity · Istituto Auxologico Italiano.

Planned enrollment
2nd of 20
1,000 · median 80
Started
2023
with 6 others
Observational
20 of 42
5 open now
Primary completion
2025-12
later than 3 of 11 live
Registered
36th of 42
by date

Among the 42 studies in Obesity by Istituto Auxologico Italiano, this one is the 2nd largest by planned enrollment of the 20 observational ones that give a count, is one of 7 that started in 2023, is one of 20 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 36th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 42 studies in Obesity by Istituto Auxologico Italiano are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Obesity by Istituto Auxologico Italiano, or all of them as a file.
02

Study summary

Overweight and obesity are increasingly prevalent worldwide. Weight excess increases the risk of in developing the metabolic syndrome, which is composed by a set of cardiometabolic risk factors such as abdominal adiposity, dyslipidemia, high blood pressure and elevated fasting glucose levels. Obesity and the metabolic syndrome are known to be risk factors for the development of chronic kidney disease. It is not clear however, whether they can be considered independent risk factors for impaired renal function and renal damage. Whereas obesity may represent an independent risk factor for renal damage, it is not clear yet if the contemporaneous presence of obesity and metabolic alterations is associated with an additional increase in the risk.

It may be important to understand the relationship between obesity, metabolic syndrome and renal health, as treatment strategies may be different for the two metabolic phenotypes of obesity, i.e., metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) patients.

The primary objective of this multicentre observational prospective study is to assess the relationship between metabolic phenotype and reduced renal function (glomerular filtration rate \<90 ml/min/1.73m2 or microalbuminuria 30-300 mg/24h) in a population of 1000 patients with overweight or obesity.

The secondary aim is to study the association between diet quality, consumption of ultra-processed foods and indicators of reduced renal function and renal damage.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Metabolic phenotype
  • Renal function
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

1000 patients with weight excess or overweight (BMI > 25 kg/m2)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 60 years
  • at least 25 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Diabetes mellitus
  • Renal disease
  • Systemic diseases with possible renal involvement
  • Agonistic physical activity
  • Heart failure
  • Pharmacologcal treatment with RAAS-inhibitors, sartans, thiazide diuretics, loop diuretics
  • Urinary tract infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults with weight excess

    Other: Diet

Interventions

  • OtherDiet

    Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months

06

What researchers measure

Primary outcomes

  1. Glomerular filtration rate

    Change in glomerular filtration after dietary intervention of 12 months

    Time frame: At baseline and after 12 months of dietary intervention programme

  2. Microalbuminuria

    Change in microalbuminuria after dietary intervention of 12 months

    Time frame: At baseline and after 12 months of dietary intervention programme

  3. Glycemia

    Change in glycemia after dietary intervention of 12 months

    Time frame: At baseline and after 12 months of dietary intervention programme

  4. Body mass index

    Change in body mass index after dietary intervention of 12 months

    Time frame: At baseline and after 12 months of dietary intervention programme

07

Study locations

2 of 2 sites recruiting
  • Istituto Auxologico Italiano, Città Studi ICANS
    Milan, 20100, Italy
    Recruiting
  • Programma Infradipartimentale di Dietoterapia nel Trapianto e nell' Insufficienza Renale Cronica, DAI di Medicina Interna ad Indirizzo Specialistico, del Policlinico Federico II di Napoli
    Naples, Italy
    Recruiting
    • Bruna Guida, Prof. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2025, 28 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 28 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2024
First posted
Mar 29, 2024
StartActual
Aug 1, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06338631
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Aug 1, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 3, 2025

Study contacts

Alberto Battezzati, Prof
Contact
a.battezzati@auxologico.it
+390261911
Luca Grappiolo
Contact
luca.grappiolo@auxologico.it
+390261911 ext. 2894

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion